BioSpace News Archive

Phase II CITYSCAPE trial shows promising results adding tiragolumab to Tecentriq in people with PD-L1-positive metastatic non-small cell lung cancer

NUBEQA reduced the risk of death by 31 percent (HR=0.69, 95% CI 0.53-0.88; p=0.003) compared to placebo in its secondary endpoint of overall survival in men with non-metastatic castration-resistant prostate cancer (nmCRPC)

AstraZeneca will present ground-breaking new results across its broad portfolio of cancer medicines during the 2020 American Society of Clinical Oncology ASCO20 Virtual Scientific Program, May 29 to May 31, 2020.

Align Technology, Inc. (NASDAQ: ALGN) today announced that due to circumstances related to the COVID-19 pandemic and to prioritize the health and well-being of our stockholders, employees, officers, directors and their families, the time and location of the Company’s 2020 Annual Meeting of Stockholders (including any adjournments or postponements, the “Annual Meeting”)

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa,” “we,” and “our”) announced today that it is commencing a public offering of 1,800,000 of its Class A common shares.

PDS Biotechnology Corporation announced the publication of its abstract on preclinical studies of PDS0102 at the American Society of Clinical Oncology Virtual Scientific Program being held May 29-31, 2020.

Latest Phase 1/2 LIBRETTO-001 registrational trial data examining Retevmo™ (selpercatinib) demonstrate commitment to advancing precision medicines for hard-to-treat tumor types

Akumin Inc. announced its financial results and management’s discussion and analysis for the quarter-ended March 31, 2020 would be available on or before June 5, 2020 due to logistics and delays caused by the COVID-19 pandemic.

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced initial data from the FORWARD II study evaluating mirvetuximab soravtansine in combination with Avastin® (bevacizumab) in patients with medium and high folate receptor alpha (FRα)-expressing recurrent ovarian cancer for whom a non-platinum based combination regimen is appropriate.

Tarveda Therapeutics®, Inc., a clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin® miniature drug conjugates, today announced the complete data from the Phase 1 dose escalation portion of a Phase 1/2a study of PEN-866 in advanced solid tumor malignancies